JP7346300B2 - 早期バイオマーカーであるユビキチンカルボキシ末端ヒドロラーゼｌ１を使用する、ヒト対象における外傷性脳損傷の程度の診断及び決定の一助となるための方法 - Google Patents

早期バイオマーカーであるユビキチンカルボキシ末端ヒドロラーゼｌ１を使用する、ヒト対象における外傷性脳損傷の程度の診断及び決定の一助となるための方法 Download PDF

Info

Publication number
JP7346300B2
JP7346300B2 JP2019552078A JP2019552078A JP7346300B2 JP 7346300 B2 JP7346300 B2 JP 7346300B2 JP 2019552078 A JP2019552078 A JP 2019552078A JP 2019552078 A JP2019552078 A JP 2019552078A JP 7346300 B2 JP7346300 B2 JP 7346300B2
Authority
JP
Japan
Prior art keywords
sample
hours
uch
level
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019552078A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020512550A5 (https=
JP2020512550A (ja
Inventor
マクイストン，ベス
ロジャーズ，ジャスティン
ダトワイラー，ソール
マリノ，ジェイミー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of JP2020512550A publication Critical patent/JP2020512550A/ja
Publication of JP2020512550A5 publication Critical patent/JP2020512550A5/ja
Application granted granted Critical
Publication of JP7346300B2 publication Critical patent/JP7346300B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/032—Transmission computed tomography [CT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
    • A61B6/501—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for diagnosis of the head, e.g. neuroimaging or craniography
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/02—Thioester hydrolases (3.1.2)
    • C12Y301/02015—Ubiquitin thiolesterase (3.1.2.15)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Radiology & Medical Imaging (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
JP2019552078A 2017-03-23 2018-03-23 早期バイオマーカーであるユビキチンカルボキシ末端ヒドロラーゼｌ１を使用する、ヒト対象における外傷性脳損傷の程度の診断及び決定の一助となるための方法 Active JP7346300B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762475662P 2017-03-23 2017-03-23
US62/475,662 2017-03-23
US15/934,541 2018-03-23
US15/934,541 US11016092B2 (en) 2017-03-23 2018-03-23 Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase L1
PCT/US2018/024112 WO2018175942A1 (en) 2017-03-23 2018-03-23 Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1

Publications (3)

Publication Number Publication Date
JP2020512550A JP2020512550A (ja) 2020-04-23
JP2020512550A5 JP2020512550A5 (https=) 2023-06-27
JP7346300B2 true JP7346300B2 (ja) 2023-09-19

Family

ID=61913679

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019552078A Active JP7346300B2 (ja) 2017-03-23 2018-03-23 早期バイオマーカーであるユビキチンカルボキシ末端ヒドロラーゼｌ１を使用する、ヒト対象における外傷性脳損傷の程度の診断及び決定の一助となるための方法

Country Status (4)

Country Link
US (3) US11016092B2 (https=)
JP (1) JP7346300B2 (https=)
CA (2) CA3261113A1 (https=)
WO (1) WO2018175942A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3261113A1 (en) 2017-03-23 2025-10-27 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
WO2018191531A1 (en) 2017-04-15 2018-10-18 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
ES3053676T3 (en) 2017-04-28 2026-01-23 Abbott Lab Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
US10866251B2 (en) 2017-05-25 2020-12-15 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
JP7269182B2 (ja) 2017-05-30 2023-05-08 アボット・ラボラトリーズ 心臓トロポニンｉ及び早期バイオマーカーを使用する、ヒト対象における軽度外傷性脳損傷を診断及び査定する一助となるための方法
US11169159B2 (en) 2017-07-03 2021-11-09 Abbott Laboratories Methods for measuring ubiquitin carboxy-terminal hydrolase L1 levels in blood
JP7379165B2 (ja) 2017-12-09 2023-11-14 アボット・ラボラトリーズ Ｇｆａｐとｕｃｈ－ｌ１との組合せを使用する、ヒト対象における外傷性脳損傷を診断及び査定する一助となるための方法
EP3721233A2 (en) 2017-12-09 2020-10-14 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
CN111699391A (zh) 2017-12-29 2020-09-22 雅培实验室 用于诊断和评估创伤性脑损伤的新型生物标志物和方法
US20230135030A1 (en) 2018-11-26 2023-05-04 Baseline Global, Inc. Methods, Systems, and a Kit for Diagnosis, Detection, Monitoring & Treatment of Traumatic Brain Injury
US20230349926A1 (en) * 2020-09-22 2023-11-02 Ohio State Innovation Foundation Methods, compositions, and kits for detecting and measuring endothelial injury in normal and diseased human central nervous system (cns)
JP2023552755A (ja) * 2020-12-01 2023-12-19 アボット・ラボラトリーズ 頭部コンピュータ断層撮影スキャンの結果が外傷性脳損傷（ｔｂｉ）に関して陰性の対象においてｔｂｉを判定するための１種以上のバイオマーカーの使用
US20220381796A1 (en) * 2021-05-18 2022-12-01 Abbott Laboratories Methods of evaluating brain injury in a pediatric subject
WO2022266034A1 (en) * 2021-06-14 2022-12-22 Abbott Laboratories Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
JP2024538608A (ja) * 2021-09-30 2024-10-23 アボット・ラボラトリーズ 脳の損傷を診断する方法及びシステム
WO2025188956A2 (en) * 2024-03-06 2025-09-12 Hollister Incorporated Device and method for detecting biomarkers in stoma dejecta and model dejecta

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012500388A (ja) 2008-08-11 2012-01-05 バンヤン・バイオマーカーズ・インコーポレーテッド 神経学的状態のバイオマーカー検出方法およびアッセイ
US20120202231A1 (en) 2009-07-18 2012-08-09 Kevin Ka-Wang Wang Synergistic biomarker assay of neurological condition using s-100b

Family Cites Families (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
DE229046T1 (de) 1985-03-30 1987-12-17 Marc Genf/Geneve Ballivet Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5635600A (en) 1986-07-07 1997-06-03 Trustees Of Dartmouth College Bifunctional and heteroantibodies specific for the high affinity Fc receptor for immunoglobulin G on human mononuclear phagocytes
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
DE3750503T2 (de) 1986-10-22 1995-02-09 Abbott Lab Chemilumineszierende Acridinium- und Phenantridiniumsalze.
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5006309A (en) 1988-04-22 1991-04-09 Abbott Laboratories Immunoassay device with liquid transfer between wells by washing
US5089424A (en) 1988-06-14 1992-02-18 Abbott Laboratories Method and apparatus for heterogeneous chemiluminescence assay
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5241070A (en) 1988-09-26 1993-08-31 Ciba Corning Diagnostics Corp. Nucleophilic polysubstituted aryl acridinium esters and uses thereof
US5063081A (en) 1988-11-14 1991-11-05 I-Stat Corporation Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
CA2107894C (en) 1991-04-10 2003-10-14 Kenneth F. Buechler Crosstalk inhibitors and their uses
EP0579767B1 (en) 1991-04-11 2000-08-23 Biosite Diagnostics Inc. Novel conjugates and assays for simultaneous detection of multiple ligands
CA2069530A1 (en) 1991-06-03 1992-12-04 Cass J. Grandone Reagent pack for immunoassays
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5352803A (en) 1992-03-30 1994-10-04 Abbott Laboratories 5(6)-methyl substituted fluorescein derivatives
JP3327551B2 (ja) 1992-03-30 2002-09-24 アボツト・ラボラトリーズ 流体試料中のチロキシンを検出・定量するための試薬および方法
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
DE69534347T2 (de) 1994-01-31 2006-05-24 Trustees Of Boston University, Boston Bibliotheken aus Polyklonalen Antikörpern
AU692239B2 (en) 1994-03-07 1998-06-04 Medarex, Inc. Bispecific molecules having clinical utilities
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US6111166A (en) 1994-09-19 2000-08-29 Medarex, Incorporated Transgenic mice expressing human Fcα and β receptors
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
AU705616B2 (en) 1995-04-21 1999-05-27 Cell Genesys, Inc. Generation of large genomic DNA deletions
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
MX336813B (es) 1996-02-09 2016-02-02 Abbvie Biotechnology Ltd Anticuerpos humanos que ligan el tnfa humano.
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US6017517A (en) 1996-12-18 2000-01-25 The Dial Corporation Method for treating human nails
ATE332368T1 (de) 1997-01-21 2006-07-15 Gen Hospital Corp Selektion von proteinen mittels rns-protein fusionen
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6682928B2 (en) 1997-12-02 2004-01-27 Medarex, Inc. Cells expressing anti-Fc receptor binding components
AU2978899A (en) 1998-03-03 1999-09-20 Abgenix, Inc. Cd147 binding molecules as therapeutics
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
CZ302706B6 (cs) 1998-12-23 2011-09-14 Pfizer Inc. Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek
US6231768B1 (en) 1999-01-19 2001-05-15 Nalco Chemical Company Rheology modification of settled solids in mineral processing
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
HUP0200575A3 (en) 1999-03-25 2004-11-29 Abbott Gmbh & Co Kg Human antibodies that bind human il-12 and methods for producing
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US6438498B1 (en) 2000-02-10 2002-08-20 I-Stat Corporation System, method and computer implemented process for assaying coagulation in fluid samples
CA2399148A1 (en) 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
KR100919593B1 (ko) 2000-06-29 2009-09-29 아보트 러보러터리즈 이중 특이성 항체 및 이의 제조 방법 및 이를 포함하는 조성물
US20030199000A1 (en) 2001-08-20 2003-10-23 Valkirs Gunars E. Diagnostic markers of stroke and cerebral injury and methods of use thereof
DK2093286T3 (da) 2001-10-01 2013-05-13 Dyax Corp Flerkædede, eukaryote displayvektorer og anvendelser deraf
US7419821B2 (en) 2002-03-05 2008-09-02 I-Stat Corporation Apparatus and methods for analyte measurement and immunoassay
US20060134713A1 (en) 2002-03-21 2006-06-22 Lifescan, Inc. Biosensor apparatus and methods of use
US20040018577A1 (en) 2002-07-29 2004-01-29 Emerson Campbell John Lewis Multiple hybrid immunoassay
US7723099B2 (en) 2003-09-10 2010-05-25 Abbott Point Of Care Inc. Immunoassay device with immuno-reference electrode
US7682833B2 (en) 2003-09-10 2010-03-23 Abbott Point Of Care Inc. Immunoassay device with improved sample closure
DK2341350T3 (en) 2003-09-20 2018-02-05 Electrophoretics Ltd DIAGNOSTIC PROCEDURE FOR BRAKE INJURY-RELATED DISORDERS BASED ON DJ-1 DETECTION
US7396654B2 (en) 2004-04-15 2008-07-08 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for traumatic brain injury
US8492107B2 (en) 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
ES2367311T3 (es) 2004-04-15 2011-11-02 University Of Florida Research Foundation, Inc. Productos de degradación proteolítica de map-2 como biomarcadores de diagnóstico para las lesiones neurales.
US20140303041A1 (en) 2004-04-15 2014-10-09 University Of Florida Research Foundation Inc. In vitro diagnostic devices for nervous system injury and other neural disorders
CN103382434B (zh) 2005-01-18 2016-05-25 生物概念股份有限公司 利用含排列成图案的立柱的微通道分离细胞
WO2007009125A2 (en) 2005-07-14 2007-01-18 Nano-Ditech Corporation Microfluidic devices and methods of preparing and using the same
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
WO2009078970A1 (en) * 2007-12-14 2009-06-25 Biotium, Inc. Fluorescent compounds
US7914734B2 (en) 2007-12-19 2011-03-29 Singulex, Inc. Scanning analyzer for single molecule detection and methods of use
WO2009100131A2 (en) 2008-02-04 2009-08-13 Banyan Biomarkers, Inc. Process to diagnose or treat brain injury
US20140342381A1 (en) 2008-08-11 2014-11-20 Banyan Biomarkers, Inc. Devices and methods for biomarker detection process and assay of neurological condition
PL2403645T3 (pl) 2009-03-06 2017-05-31 President And Fellows Of Harvard College Mikroprzepływowe, elektrochemiczne urządzenia
AU2010262952B2 (en) 2009-06-19 2016-01-07 Banyan Biomarkers, Inc. Biomarker assay of neurological condition
US20170315136A9 (en) 2009-06-19 2017-11-02 Banyan Biomarkers, Inc. Biomarker assay of neurological condition
AU2010291933B2 (en) 2009-09-14 2016-09-08 Banyan Biomarkers, Inc. Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury
WO2011160096A2 (en) 2010-06-17 2011-12-22 Banyan Biomarkers, Inc. Glial fibrillary acidic protein, autoantigens and autoantibodies thereto as biomarkers of neural injury or neurological disorder or condition
WO2012051519A2 (en) 2010-10-14 2012-04-19 The Johns Hopkins University Biomarkers of brain injury
WO2012170998A1 (en) 2011-06-10 2012-12-13 Cornell University Immobilized protein system for rapid and enhanced multiplexed diagnostics
US20120322682A1 (en) 2011-06-20 2012-12-20 William Marsh Rice University Brain injury biomarker panel
US20140370531A1 (en) 2011-12-14 2014-12-18 University Of Rochester Method of diagnosing mild traumatic brain injury
WO2014124174A2 (en) 2013-02-08 2014-08-14 Children's Hospital Los Angeles Circulating bmec and related cells as biomarkers of cns diseases associated with the blood-brain-barrier disorders
US9157910B2 (en) 2013-03-15 2015-10-13 Abbott Laboratories Assay with increased dynamic range
WO2014194329A1 (en) 2013-05-31 2014-12-04 Banyan Biomarkers, Inc. NEURAL SPECIFIC S100β FOR BIOMARKER ASSAYS AND DEVICES FOR DETECTION OF A NEUROLOGICAL CONDITION
US9265441B2 (en) 2013-07-12 2016-02-23 Siemens Aktiengesellschaft Assessment of traumatic brain injury
US10534003B2 (en) 2013-07-17 2020-01-14 The Johns Hopkins University Multi-protein biomarker assay for brain injury detection and outcome
WO2015066211A1 (en) 2013-10-29 2015-05-07 Banyan Biomarkers, Inc. Uch-l1 isoforms, assays and devices for detection of a neurological condition
US20150224499A1 (en) 2014-02-13 2015-08-13 SFC Fluidics, Inc. Automated Microfluidic Sample Analyzer Platforms for Point of Care
EP3129780A4 (en) 2014-04-07 2017-12-13 Iron Horse Diagnostics Inc. Traumatic brain injury and neurodegenerative biomarkers, methods, and systems
AU2015323168B2 (en) 2014-09-22 2020-07-02 Japan Science And Technology Agency Method for detecting target molecule, and kit for use in said method
WO2016055148A2 (en) 2014-10-06 2016-04-14 Université De Genève Markers and their use in brain injury
MX2017012742A (es) 2015-04-03 2017-11-15 Abbott Lab Dispositivos y metodos para el analisis de muestras.
EP3278108B1 (en) 2015-04-03 2021-03-17 Abbott Laboratories Devices and methods for sample analysis
FI20155280A7 (fi) 2015-04-15 2016-10-16 Medicortex Finland Oy Aivovamman prognostisia ja diagnostisia glykaanipohjaisia biomarkkereita
WO2016196522A1 (en) 2015-05-29 2016-12-08 Cedars-Sinai Medical Center Correlated peptides for quantitative mass spectrometry
CN105085629A (zh) 2015-08-12 2015-11-25 浙江聚康生物工程有限公司 人gfap抗原决定簇多肽、抗体及其体外诊断试剂盒
CN110383068A (zh) 2016-10-03 2019-10-25 雅培实验室 评估患者样品中uch-l1状态的改进方法
US11078298B2 (en) 2016-10-28 2021-08-03 Banyan Biomarkers, Inc. Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
WO2018136825A1 (en) 2017-01-19 2018-07-26 Cedars-Sinai Medical Center Highly multiplexed and mass spectrometry based methods to measuring 72 human proteins
CA3261113A1 (en) * 2017-03-23 2025-10-27 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
WO2018191531A1 (en) 2017-04-15 2018-10-18 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
ES3053676T3 (en) * 2017-04-28 2026-01-23 Abbott Lab Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
WO2018217792A1 (en) 2017-05-23 2018-11-29 Immunarray USA, Inc. Biomarker levels and neuroimaging for detecting, monitoring and treating brain injury or trauma
US10866251B2 (en) 2017-05-25 2020-12-15 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
JP7269182B2 (ja) 2017-05-30 2023-05-08 アボット・ラボラトリーズ 心臓トロポニンｉ及び早期バイオマーカーを使用する、ヒト対象における軽度外傷性脳損傷を診断及び査定する一助となるための方法
US20190091687A1 (en) 2017-09-28 2019-03-28 Maha Abdullah A. Alhasnani Safe blood pregnancy test at home
EP3721233A2 (en) 2017-12-09 2020-10-14 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
JP7379165B2 (ja) 2017-12-09 2023-11-14 アボット・ラボラトリーズ Ｇｆａｐとｕｃｈ－ｌ１との組合せを使用する、ヒト対象における外傷性脳損傷を診断及び査定する一助となるための方法
CN111699391A (zh) 2017-12-29 2020-09-22 雅培实验室 用于诊断和评估创伤性脑损伤的新型生物标志物和方法
US20190302127A1 (en) 2018-03-30 2019-10-03 Sysmex Corporation Method for diagnosing traumatic brain injury
WO2019199869A1 (en) 2018-04-10 2019-10-17 Quanterix Corporation Quantification of biomarkers present in physiological samples
US20220288588A1 (en) 2019-08-05 2022-09-15 Auer Precision Company, Inc. Microfluidic passive plasma separation device and method
KR102464243B1 (ko) 2020-04-01 2022-11-08 프리시젼바이오 주식회사 외상성 뇌손상 바이오마커 검출용 시분해 형광분석 측방유동 분석장치 및 이를 이용한 외상성 뇌손상 바이오마커 측정방법
CN112881700A (zh) 2021-01-12 2021-06-01 瑞吉瑞得医药生物科技(无锡)有限公司 一种用于全血样本预处理的磷酸盐缓冲液及其使用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012500388A (ja) 2008-08-11 2012-01-05 バンヤン・バイオマーカーズ・インコーポレーテッド 神経学的状態のバイオマーカー検出方法およびアッセイ
US20120202231A1 (en) 2009-07-18 2012-08-09 Kevin Ka-Wang Wang Synergistic biomarker assay of neurological condition using s-100b

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DIAZ-ARRASTIA, R. et al.，Acute Biomarkers of Traumatic Brain Injury: Relationship between Plasma Levels of Ubiquitin C-Terminal Hydrolase-L1 and Glial Fibrillary Acidic Protein，Journal of Neurotrauma，2014年，Vol.31，pp.19-25
LEE, J.Y. et al.，A Role of Serum-Based Neuronal and Glial Markers as Potential Predictors for Distinguishing Severity and Related Outcomes in Traumatic Brain Injury，J Korean Neurosurg Soc，2015年，VOl.58, No.2，pp.93-100
MONDELLO, S. et al.，Serum Concentrations of Ubiquitin C-Terminal Hydrolase-L1 and Glial Fibrillary Acidic Protein after Pediatric Traumatic Brain Injury，Scientific Reports，2016年，6:28203，pp.1-8，DOI: 10.1038/srep28203
眞重 文子，ROC曲線の作成と最適なカットオフ値の求め方，生物試料分析，2005年，Vol.28, No.2，pp.133-136

Also Published As

Publication number Publication date
WO2018175942A1 (en) 2018-09-27
US12163958B2 (en) 2024-12-10
US11016092B2 (en) 2021-05-25
CA3261113A1 (en) 2025-10-27
US20180313837A1 (en) 2018-11-01
US20250123279A1 (en) 2025-04-17
CA3052513A1 (en) 2018-09-27
US20210341481A1 (en) 2021-11-04
JP2020512550A (ja) 2020-04-23

Similar Documents

Publication Publication Date Title
JP7674439B2 (ja) Ｇｆａｐとｕｃｈ－ｌ１との組合せを使用する、ヒト対象における外傷性脳損傷を診断及び査定する一助となるための方法
US20250020665A1 (en) Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
US20250123279A1 (en) Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
JP7344801B2 (ja) グリア原線維性酸性タンパク質（ｇｆａｐ）及び／又はユビキチンカルボキシ末端ヒドロラーゼｌ１（ｕｃｈ－ｌ１）を使用する、整形外科損傷を負っており、軽度外傷性脳損傷（ｔｂｉ）などの頭部への損傷を負ったか又は負った可能性がある対象についての診断及び査定の一助となるための方法
JP7344797B2 (ja) 早期バイオマーカーを使用する、ヒト対象における外傷性脳損傷の、超急性の診断及び決定の一助となるための方法
JP7269182B2 (ja) 心臓トロポニンｉ及び早期バイオマーカーを使用する、ヒト対象における軽度外傷性脳損傷を診断及び査定する一助となるための方法
EP3635407B1 (en) Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
EP3602069A1 (en) Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
JP2025501182A (ja) Ｔｂｉ（外傷性脳損傷）に対して陰性である、頭部コンピュータ断層撮影（ｃｔ）スキャンを受けたことがある又は頭部ｃｔスキャンを受けたことがない対象において亜急性外傷性脳損傷（ｔｂｉ）を決定するためのバイオマーカーの使用
JP2024534849A (ja) 脳の損傷を診断する方法及びシステム
US20240110928A1 (en) Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
US20220381796A1 (en) Methods of evaluating brain injury in a pediatric subject
HK40015192A (en) Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210316

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210316

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230314

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20230615

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230808

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230906

R150 Certificate of patent or registration of utility model

Ref document number: 7346300

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150